Bausch Health Launches CABTREO for Acne Treatment in Canada

Bausch Health, Canada Inc. has announced the availability of its new acne treatment, CABTREO, for users of public drug plans in Ontario and Nova Scotia, and certain federal programs. CABTREO is a topical gel that combines an antibiotic, a retinoid, and an antibacterial agent to effectively treat acne vulgaris in patients aged 12 and older. Health Canada has approved this as the first triple-combination topical treatment for acne.

The treatment is now accessible to these public plan beneficiaries as well as most private insurance holders. The formulation aims to ease the physical and mental impact of acne on patients. In clinical trials, CABTREO showed significant efficacy with around 50% treatment success after 12 weeks. Common side effects include mild to moderate skin irritation.